Connect with us
Oryzon Genomics reported a loss of €2.4 million in the first half of 2024, slightly less than the €2.5 million loss in 2023. Financial losses decreased...
The Spanish biotechnology sector, detailed in the AseBio 2023 Report, generated over €16.6 billion in 2022, 1.5% of GDP, and contributed 162,845 jobs. Private financing reached...
Boehringer Ingelheim Spain significantly increased its R&D&I investment to 62.7 million euros, up 36% from the previous year, representing 11.5% of net sales. Their human health...
Eli Lilly's U.S. revenues grew by 39% to 6,188.1 million euros, with international revenues up 10% to 2.7 billion euros. R&D costs rose by 29.5%, while...
Within the health sector, 20% of investment in R&D came from the ten largest companies by investment, which allocated €53.9 billion, €10 billion more than the...
Looking at application sectors, although the activity of biotech companies in Italy remains largely concentrated in human health (just under 50 percent), between 2014 and 2021...
Spanish biotech companies maintain their leading position in the industrial sector in science with the highest percentage of researchers. The research workplaces Spain in the ninth position...
Boehringer Ingelheim reached a sales figure of €24.1 billion in 2022, which translates into a year-on-year rise of 10.5%. In 2022, the Spanish subsidiary registered an...
AstraZeneca’s commitment to the Spanish territory can also be seen in the creation of infrastructure since it has allocated a total of €5.5 million for the...
Each of the clinics that make up IVI RMA's worldwide network (more than 65 clinics) is likely to pursue one or more of the lines of...